Bodyweight Change as an Adverse Effect of Drug Treatment: Mechanisms and Management

Drug Safety

Volumn 14, Issue 5, 1996, Pages 329-342

  Pijl, Hanno ^a   Meinders, A Edo ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CORTICOSTEROID; DANAZOL; INSULIN; LITHIUM; LOXAPINE; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

BODY FAT; BODY MASS; BODY WEIGHT; BREAST CANCER; CALORIC RESTRICTION; COUNSELING; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; ENERGY BALANCE; EXERCISE; HEALTH HAZARD; HUMAN; HYPOTHALAMUS; MIGRAINE; NONHUMAN; NUTRITION; OBESITY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BODY WEIGHT; HUMANS; HYPOGLYCEMIC AGENTS; PHARMACEUTICAL PREPARATIONS; PSYCHOTROPIC DRUGS; WEIGHT GAIN;

EID: 0029967145     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199614050-00005     Document Type: Article

References (137)

1. Forbes JM. Metabolic aspects of the regulation of voluntary food intake and appetite. Nutr Res Rev 1988; 1: 145-68
2. Morley JE. An approach to the development of drugs for appetite disorders. Neuropsychobiology 1989; 21: 22-30
3. Schwartz MS, Figlewicz DP, Baskin DG, et al. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 1992; 13: 387-414
4. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-95
5. Leibowitz SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 1992; 15:491-7
6. Pijl H, Meinders AE. Brain serotonin and food selection: history and current perceptions. J Serot Res 1994; 1: 21-45
7. Leibowitz SF, Weiss GF, Shor Posner G. Hypothalamic serolonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin Neuropharmacol 1988; 11 Suppl. 1:S51-S71
8. Leibowitz SF, Weiss GF, Walsh UA, et al. Medial hypothalamic serotonin: role in circadian patterns of feeding and macronutrient selection. Brain Res 1989; 503: 132-40
9. 2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine. Eur J Pharmacol 1985; 115: 11-91
10. Leibowitz SF. Catecholaminergic mechanisms of the lateral hypothalamus: their role in the mediation of amphetamine anorexia. Brain Res 1975; 98: 529-45
11. Zarrindast MR, Owji AA, Hosseini Nia T. Evaluation of dopamine receptor involvement in rat feeding behaviour. Gen Pharmacol 1991; 22: 1011-6
12. Angel I. Central receptors and recognition sites mediating the effects of monoamines and anorectic drugs on feeding behavior. Clin Neuropharmacol 1990; 13: 361-91
13. Jansky L. Humoral thermogenesis and its role in maintaining energy balance. Physiol Rev 1995; 75: 237-59
14. Pi-Sunyer FX. Medical Hazards of Obesity. Ann Intern Med 1993; 119: 655-60
15. Bray GA, Gray DS. Treatment of obesity: an overview. Diabetes Metab Rev 1988; 4: 653-79
16. Arenillas L. Amitriptyline and body weight. Lancet 1964; I: 432-31
17. Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973; 123: 501-7
18. Kupfer DJ, Coble PA. Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979; 41: 535-44
19. Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. J Affect Disord 1984; 7: 133-8
20. Fernstrom MH, Krowinski RL, Kupfer DJ. Chronic imipramine treatment and weight gain. Psychiatry Res 1986; 17: 269-73
21. Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987; 48: 27-8
22. Orzack MH, Cole JO, Friedman L, et al. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiology 1986; 15: 28-30
23. Gottfries CG. Influence of depression and antidepressants on weight. Acta Psychiatr Scand 1981; 290: 353-6
24. Harris B, Young J. Hughes B. Appetite and weight change in patients presenting with depressive illness. J Affect Disord 1984; 6: 331-9
25. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium [review]. J Clin Psychopharmacol 1988; 8: 323-30
26. Szarek BL, Brandt DM. A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients. J Nerv Ment Dis 1993; 181: 702-4
27. Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management [review]. Clin Neuropharmacol 1988; 11 Suppl. 1:S194-206
28. Paradis CF, Stack JA, George CJ, et al. Nortriptyline and weight change in depressed patients over 60. J Clin Psychopharmacol 1992; 12: 246-50
29. Fernstrom MH, Krowinski RL, Kupfer DJ. Appetite and food preference in depression: effects of imipramine treatment. Biol Psychiatry 1987; 22: 529-39
30. Robinson DS, Corcella J, Feighner JP, et al. A comparison of trazodone, amoxapine and maprotiline in the treatment of endogenous depression: results of a multicenter study. Curr Ther Res 1984; 35: 549-60
31. Whitworth AB, Fleischhacker WW. Adverse effects of antipsychotic drugs [review]. Int Clin Psychopharmacol 1995; 9 Suppl. 5: 21-7
32. Kessel JB, Simpson GM. Tricyclic and tetracyclic drugs. In: Kaplan HIS, Adock BJ, editors. Comprehensive textbook of psychiatry/VI. Baltimore: Williams and Wilkins, 1995: 2096-112
33. Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994; 30: 193-207
34. Fernstrom MH. Depression, antidepressants, and body weight change [discussion]. Ann N Y Acad Sci 1989; 575: 31-9
35. Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology 1992; 106 Suppl: S98-101
36. Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J Clin Psychopharmacol 1984; 4: 270-8
37. Rabkin J, Quitkin FM, McGrath P et al. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol 1985; 5: 2-9
38. Gander DR. Treatment of depressive illness with combined antidepressants. Lancet 1965; 11: 107
39. Winston F. McCann ML. Antidepressant drugs and excessive weight gain. Br J Psychiatry 1972; 120: 693-4
40. Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr 1995; 61: 1020-5
41. Rothwell NJ, Stock MJ. Effect of diet and fenfluramine on thermogenesis in the rat: possible involvement of serotonergic mechanisms. Int J Obes 1987; 11: 319-24
42. Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull 1988; 24: 220-3
43. Harris B, Ashford J. Maintenance antidepressants and weight gain: a comparison of fluvoxamine and amitriptyline. Br J Clin Res 1991; 2: 81-8
44. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: u comparison study of lour medications. Psychiatry Res 1988; 26: 265-71
45. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993; 342: 1419
46. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53 (1): 84-8
47. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149: 689-90
48. Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine [see comments]. Am J Psychiatry 1990; 147: 503-4
49. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-53
50. Povlsen UJ, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176-85
51. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-72
52. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55: Suppl B: 157-60
53. Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11: 182-9
54. Gordon HL, Groth C. Weight change during and after hospital treatment. Arch Gen Psychiatry 1964; 10: 187-91
55. Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979; 40: 528-30
56. Klett CJ, Caffey EM. Weight changes during treatment with phenothiazine derivates. J Neuropsychiatry 1960; 2: 102-8
57. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-7
58. Gardos G, Cole JO. Weight reduction in schizofrenics by molindone. Am J Psychiatry 1977; 134: 302-4
59. Kellner R, Rada RT, Egelman A, et al. Long term study of molindone hydrochloride in chronic schizophrenics. Curr Ther Res 1976; 20: 686-93
60. Pickar D. Prospects for pharmacotherapy of schizophrenia [review]. Lancet 1995; 345: 557-62
61. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-86
62. Parada MA, Hernandez L, Hoebel BG. Sulpride injection in the lateral hypothalamus induces feeding and drinking in rats. Pharmacol Biochem Behav 1988; 30: 917-23
63. Singh MM, DeDios LV, Kline NS, Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 1970; 9: 562-70
64. Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975; 12: 59-68
65. Roth BL, Craigo SC, Choudhary MS. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6 and 5-hydroxytryptamine 7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-10
66. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18-S27
67. Weidley EF, Setler PE, Rush JA. The serotonin blocking properties of antipsychotic drugs. Pharmacologist 1980; 22: 279
68. Mc Tavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992; 43: 713-33
69. Goodall E, Oxtoby C, Richards R, et al. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988; 153: 208-13
70. Price LH, Heninger GR. Lithium in the treatment of mood disorders [see comments]. N Engl J Med 1994; 331: 591-8
71. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol 1990; 5: 217-25
72. Kerry RJ, Liebling LI, Owen G. Weight changes in lithium responders. Acta Psychiatr Scand 1970; 46: 238-43
73. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139-47
74. Peselow ED, Dunner DL, Fieve RR, et al. Lithium carbonate and weight gain. J Affect Disord 1980; 2: 303-10
75. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. Part III. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434-41
76. Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. Acta Psychiatr Scand 1980; 62: 193-200
77. Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain [review]. Pharmacopsychiatry 1995; 28: 35-44
78. Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 1987; 7: 91-5
79. Waldmeier PC. Is there a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmacopsychiatry 1987; 20: 37-47
80. Dinesen H, Gram L, Veje A. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-9
81. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283: 557-81
82. Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 436-62
83. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666-70
84. Aston MG, Ball SG, Thomas LH, et al. Water intoxication associated with carbamazepine treatment. BMJ 1977; 1: 1134-5
85. Kimura T, Matsui K, Sato T, et al. Mechanism of carbamazepine (Tegretol) induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab 1974; 38: 356-62
86. Meinders AE, Cejka V, Robertson GL. The antidiuretic action of carbamazepine in man. Clin Sci Mol Med 1974; 47: 289-99
87. Lampl Y, Eshel Y, Rapaport A, et al. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991; 14: 251-5
88. Naruse T. Effects of repeated intravenous administration of diazepam on food intake in rats. Fundam Clin Pharmacol 1994; 8: 379-84
89. Pang S, Clark AT, Freeman LC, et al. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 75: 249-53
90. Merritt RJ, Hack SL, Kalsch M, et al. Corticosteroid therapy-induced obesity in children. Clin Pediatr 1986; 25: 149-52
91. Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy [see comments]. Lancet 1993; 342: 949-54
92. Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr 1988; 27: 387-92
93. Curtis JJ, Galla JH, Woodford SY, et al. Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1981; 1: 166-71
94. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. Part II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6
95. Keteyian SJ, Marks CR, Fedel FJ, et al. Assessment of body composition in heart transplant patients. Med Sci Sports Exerc 1992; 24: 247-52
96. Horber FF, Zurcher RM, Herren H, et al. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986; 43: 758-69
97. Hauner H, Bognar E, Blum A. Body fat distribution and its association with metabolic and hormonal risk factors in women with angiographically assessed coronary artery disease. Evidence for the presence of a metabolic syndrome. Atherosclerosis 1994; 105: 209-16
98. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? [review]. Postgrad Med J 1994; 70: 863-70
99. Tempel DL, Leibowitz SF. Adrenal steroid receptors: interactions with brain neuropeptide systems in relation to nutrient intake and metabolism [review]. J Neuroendocrinol 1994; 6: 479-501
100. Loprinzi CL, Ellison NM, Goldberg RM, et al. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Sem Oncol 1990; 17: 8-12
101. World Health Organization. The WHO multicemer trial of the vasopressor effects of combined oral contraceptives. Part I. Comparison with IUD. Contraception 1989; 40: 129-45
102. World Health Organisation. The WHO multicenter trial of the vasopressor effects of combined oral contraceptives. Part II. Lack of effect of estrogen. Contraception 1989; 40: 147-56
103. Manconi FM, Zuddas A, Piccardi MP, et al. Behavioural and biochemical effects of flunarizine on the dopaminergic system in rodents. Cephalalgia 1987; 7: 420-1
104. Smith MA, Youngkin EQ. Current perspectives on combination oral contraceptives [review]. Clin Pharm 1984; 3: 485-96
105. Oelkers W, Foidart JM. Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-21
106. PEPI Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273; 199-208
107. Renier M, Buytaert P. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene. Contraception 1991; 43: 413-21
108. Weber-Diehl F, Lehnert J, Lachnit U. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial. Contraception 1993; 48: 291-301
109. O'Sullivan AJ, Hoffman DM, Ho KK. Estrogen, lipid oxidation, and body fat [letter]. N Engl J Med 1995; 333: 669-70
110. Bruera E, Macmillan K, Kuehn N, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279-82
111. Alexieva-Figusch J, Van Gilse HA, Hop WC, et al. Progestin therapy in advanced breast cancer: megestrol acetate - an evaluation of 160 treated cases. Cancer 1980; 46: 2369-72
112. Aisner J, Parnes H, Tait N. et al. Appetite stimulation and weight gain with megestrol acetate. Semin Oncol 1990; 17 Suppl. 9: 2-7
113. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus [see comments]. N Engl J Med 1992; 327: 1426-33
114. Hickey ME, Hall TR. Insulin therapy and weight change in Native-American NIDDM patients. Diabetes Care 1993; 16: 364-8
115. The Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 1993; 11: 567-73
116. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42: 1700-7
117. Hermann LS, Scherstén B, Bitzén P-O, et al. Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 1994; 17: 1100-9
118. Hermann LS, Karlsson J-E, Sjöstrand Å. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 1991; 41: 263-5
119. Josephcutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabetic Med 1990; 7: 510-4
120. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 1994; 21: 394-400
121. Groop L, Widén E, Franssila-Kallunki A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 599-605
122. McAlpine LG, McAlpine CH, Waclawski ER, et al. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. Eur J Clin Pharmacol 1988; 34: 129-32
123. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab 1991; 17: 209-12
124. Leslie P, Jung RT, Isles TE, et al. Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy. Clin Sci 1987; 73: 41-5
125. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer [review]. J Clin Oncol 1993; 11: 1418-29
126. Goodwin PA, Panzarella T, Boyd NF. Weight gain in women with localized breast cancer - a descriptive study. Breast Cancer Res Treat 1988; 11: 59-66
127. Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer-effect of tamoxifen. Breast Cancer Res Treat 1992; 22: 129-32
128. Centonze V, Magrone D, Vino M, et al. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels. Cephalalgia 1990; 10: 17-24
129. Meyboom RHB, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet 1986; II: 282
130. Baldrati A, Albano F, de Carolis P, et al. Essential tremor and flunarizine: description of a case. Cephalalgia 1987; 7: 285
131. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizutifen: a double blind study in the prophylaxis of migraine. Headache 1986; 26: 83-5
132. Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double blind investigation. Cephalalgia 1985; 5: 17-23
133. Martinez-Mir I, Navarro-Badenes J, Palop V, et al. Weight gain induced by long-term propranolol treatment [letter]. Ann Pharmacother 1993; 27: 512
134. Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300: 902-3
135. Landsberg L, Young JB. Sympathoadrenal activity and obesity - physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes 1993; 17: S29-S34
136. Lonnqvist F, Thorne A, Nillsell K, et al. A pathogenetic role of visceral fat beta-3-adrenoreceptors in obesity. J Clin Invest 1995; 95: 1109-16
137. Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients [see comments]. Ann R Coll Surg Engl 1990; 72: 296-8